The rise of GLP-1 weight-loss drugs has sparked a fast-growing interest in peptides, stirring a battle between compounding pharmacies, big pharma and regulators over access, safety and how these lab-made molecules should be supplied to patients.
Peptides are short chains of amino acids that act as tiny biological messengers, and lab-made peptide drugs aim to copy or nudge those signals to treat or improve health. Interest has spilled from clinics into the public marketplace, with products marketed for everything from weight loss to recovery and skin rejuvenation. That boom has exposed a largely unregulated trade that sits between licensed compounding pharmacies and less-vetted vendors.
Doctors point to GLP-1 drugs as the tipping point for wider peptide curiosity. “They are incredibly effective at what they do when it comes to changing body composition, benefiting metabolic health, cardiovascular health [and] neurologic health,” he said. That kind of language sells itself and drives demand well beyond patients with clear disease diagnoses.
Commercial GLP-1 offerings are usually single-dose weekly pens, which suit most people but not everyone. “There are patients I can prescribe tirzepatide to and they can do OK with a once-a-week [dose], but they end up developing nausea with that initial injection – and then by the end of the week, they’re hungry again.” Some clinicians see value in smaller, more frequent dosing for those patients.
Compounding pharmacies responded to that need by creating customized versions that allow different dosing schedules and formats. “We’ve had compounding pharmacies that have now developed compounded versions of semaglutide and tirzepatide that allow that sort of dosing flexibility,” he said. That flexibility stepped in while commercial manufacturers worked to meet surging demand.
The growth of compounding was intensified by a national shortage that pushed patients and providers to seek alternatives. “The reason compounders had to do this was because there was so much demand for GLP-1s that there was actually a national shortage.” Laws let compounders fill gaps in widespread shortages, and many invested heavily to make these alternatives available.
That availability has created friction with pharmaceutical companies, who see custom compounding as infringing on their market and intellectual property. “That creates a huge clash between commercial pharmaceutical companies and compounders, because commercial pharmaceutical companies view that as an infringement of their property,” Tatem noted. Regulators are now under pressure to balance safety with access.
Tatem has warned that tighter FDA regulation of compounding pharmacies could limit individualized patient care. “That is a real concern for clinicians like me who really care more about patient access, making sure we can get the right medication to the right patients at the right time,” he said. At the same time, regulators have moved: in September 2023, the FDA “quietly” tightened regulation of 19 peptides, effectively cutting off some channels for patients.
Many peptides in circulation were never run through the full FDA approval gauntlet, yet clinicians report limited serious safety signals over years of use. “These are compounds that haven’t gone through the full FDA approval process that you would normally see for a commercial drug, [yet] we didn’t see anything adverse,” he said. Still, emerging popularity and mixed oversight make experts urge caution.
Peptides are being tried for injury recovery, sleep, skin repair and boosting natural growth hormones, often as part of broader wellness plans rather than cures. “These were all medications that were designed to help people live well and live as healthy as possible,” the doctor told Fox News Digital. Consumers are advised to avoid gray-market products and work only with qualified physicians and reputable pharmacies.
Industry voices emphasize regulatory rigor. “affordable access to safe, effective and FDA-approved GLP-1 obesity medication like Wegovy and to protect patients from unapproved and untested knockoff drugs,” a Novo Nordisk spokesperson said in a statement. “Novo Nordisk supports FDA’s recent thorough scientific analysis and conclusion that there is no medical basis or clinical need for the continued mass compounding of unapproved semaglutide and liraglutide drugs,” they went on.
“The agency’s decision reaffirms that compounding is meant to be a rare and limited exception to FDA’s gold-standard drug approval framework that ensures that medicines in the U.S. are safe and effective.” At the same time, clinicians who treat patients seeking to feel better are watching policy closely, wary that stricter rules might limit tailored care.
The bottom line for patients is practical: fundamentals still matter — sleep, nutrition and consistent training — and peptides should be considered as potential adjuncts, not magic bullets. “The desire to function at our highest level is something that we all feel,” he said. Consumers should prioritize qualified medical advice and reputable sources when considering any peptide-based treatment.
